Technical Analysis for MBIO - Mustang Bio, Inc.

Grade Last Price % Change Price Change
grade C 5.64 112.03% 2.98
MBIO closed up 112.03 percent on Thursday, April 18, 2019, on 46.48 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. The bulls were able to push the stock to a new 52-week high. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical MBIO trend table...

Date Alert Name Type % Chg
Gilligan's Island Sell Setup Bearish Swing Setup 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
New Uptrend Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%

Older signals for MBIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.
Medicine Biopharmaceutical Cancer Immunotherapy Immune System Cancer Treatments Gene Therapy Cancer Immunotherapy Virotherapy Kite Pharma Chimeric Antigen Receptor Cancer Immunotherapy Products Cellectis T Cell
Is MBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 10.2
52 Week Low 2.18
Average Volume 806,329
200-Day Moving Average 4.732
50-Day Moving Average 3.8904
20-Day Moving Average 3.4245
10-Day Moving Average 3.407
Average True Range 0.8056
ADX 27.98
+DI 69.2666
-DI 9.8162
Chandelier Exit (Long, 3 ATRs ) 7.7832
Chandelier Exit (Short, 3 ATRs ) 5.0068
Upper Bollinger Band 4.5756
Lower Bollinger Band 2.2734
Percent B (%b) 1.46
BandWidth 67.227332
MACD Line -0.0423
MACD Signal Line -0.1617
MACD Histogram 0.1193
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.83
Resistance 3 (R3) 13.55 11.87 11.63
Resistance 2 (R2) 11.87 10.04 11.51 11.23
Resistance 1 (R1) 8.76 8.91 7.92 8.04 10.83
Pivot Point 7.08 7.08 6.67 6.72 7.08
Support 1 (S1) 3.97 5.25 3.13 3.25 0.45
Support 2 (S2) 2.29 4.12 1.93 0.05
Support 3 (S3) -0.82 2.29 -0.35
Support 4 (S4) -1.55